Rituximab Maintenance Therapy After First-Line Induction Chemoimmunotherapy for Follicular Lymphoma

    loading  Checking for direct PDF access through Ovid


Clinical Question

Is rituximab maintenance therapy after first-line induction chemoimmunotherapy for follicular lymphoma associated with improved outcomes?

Bottom Line

Compared with observation, rituximab maintenance therapy prolongs progression-free survival without an improvement in overall survival or quality of life after first-line induction chemoimmunotherapy.

Related Topics

    loading  Loading Related Articles